A Randomized Controlled Trial of Fecal Microbiota Transplantation for Parkinson's Disease: Getting It Right, if Not PARFECT

Overview

Journal J Parkinsons Dis

Publisher Sage Publications

Specialty Neurology

Date 2024 Jul 5

PMID 38968058

Authors

Milan Beckers

Bryan Coburn

Lorraine V Kalia

Bastiaan R Bloem

Affiliations

Soon will be listed here.

References

Beckers M, Bloem B, Verbeek M . Mechanisms of peripheral levodopa resistance in Parkinson's disease. NPJ Parkinsons Dis. 2022; 8(1):56. PMC: 9095610. DOI: 10.1038/s41531-022-00321-y. View

Horvath K, Aschermann Z, Acs P, Deli G, Janszky J, Komoly S . Minimal clinically important difference on the Motor Examination part of MDS-UPDRS. Parkinsonism Relat Disord. 2015; 21(12):1421-6. DOI: 10.1016/j.parkreldis.2015.10.006. View

Scheperjans F, Aho V, Pereira P, Koskinen K, Paulin L, Pekkonen E . Gut microbiota are related to Parkinson's disease and clinical phenotype. Mov Disord. 2014; 30(3):350-8. DOI: 10.1002/mds.26069. View

Kuai X, Yao X, Xu L, Zhou Y, Zhang L, Liu Y . Evaluation of fecal microbiota transplantation in Parkinson's disease patients with constipation. Microb Cell Fact. 2021; 20(1):98. PMC: 8120701. DOI: 10.1186/s12934-021-01589-0. View

DuPont H, Suescun J, Jiang Z, Brown E, Essigmann H, Alexander A . Fecal microbiota transplantation in Parkinson's disease-A randomized repeat-dose, placebo-controlled clinical pilot study. Front Neurol. 2023; 14:1104759. PMC: 10019775. DOI: 10.3389/fneur.2023.1104759. View

Cheng Y, Tan G, Zhu Q, Wang C, Ruan G, Ying S . Efficacy of fecal microbiota transplantation in patients with Parkinson's disease: clinical trial results from a randomized, placebo-controlled design. Gut Microbes. 2023; 15(2):2284247. PMC: 10841011. DOI: 10.1080/19490976.2023.2284247. View

Bruggeman A, Vandendriessche C, Hamerlinck H, De Looze D, Tate D, Vuylsteke M . Safety and efficacy of faecal microbiota transplantation in patients with mild to moderate Parkinson's disease (GUT-PARFECT): a double-blind, placebo-controlled, randomised, phase 2 trial. EClinicalMedicine. 2024; 71:102563. PMC: 11056595. DOI: 10.1016/j.eclinm.2024.102563. View

Verbeek M, Bloem B . An emerging biomarker for dopaminergic cell loss. Nat Aging. 2023; 3(10):1180-1182. DOI: 10.1038/s43587-023-00501-2. View

Fasano A, Bove F, Gabrielli M, Petracca M, Zocco M, Ragazzoni E . The role of small intestinal bacterial overgrowth in Parkinson's disease. Mov Disord. 2013; 28(9):1241-9. DOI: 10.1002/mds.25522. View

10.

Vascellari S, Palmas V, Melis M, Pisanu S, Cusano R, Uva P . Gut Microbiota and Metabolome Alterations Associated with Parkinson's Disease. mSystems. 2020; 5(5). PMC: 7498685. DOI: 10.1128/mSystems.00561-20. View

11.

Lin C, Lai H, Wu M . Gut-oriented disease modifying therapy for Parkinson's disease. J Formos Med Assoc. 2022; 122(1):9-18. DOI: 10.1016/j.jfma.2022.09.010. View

12.

Dahl Baunwall S, Lee M, Eriksen M, Mullish B, Marchesi J, Frederik Dahlerup J . Faecal microbiota transplantation for recurrent infection: An updated systematic review and meta-analysis. EClinicalMedicine. 2021; 29-30:100642. PMC: 7788438. DOI: 10.1016/j.eclinm.2020.100642. View